ARCUS BIOSCIENCES - ARCUS BIOSCIENCES INC

Explicit Guidance:

• Peak 1 (Second Line): Fully enrolled by end of current year; expected to win on Progression-Free Survival (PFS) as primary endpoint, with statistical power recycled to demonstrate Overall Survival (OS) benefit (targeting a hazard ratio better than the 0.85 seen in LightSpark 11).
• Peak 20 (First Line): Commencing enrollment at end of current year; primary endpoint is PFS; expects to significantly reduce primary progression rates compared to ipilimumab/nivolumab (Ip/Nevo).
• Late Line (Peak 30): Development of Phase 3 study combining Casatafan with Tivozanib (TiVo) is underway; will enroll all-comers (including those with prior HIF-2-alpha exposure).
• Commercial Outlook: Casatafan projected to represent a $5–10 billion commercial opportunity; specific targets include a $4 billion+ opportunity in the first line and a $2 billion opportunity in the second line.
• Treatment Duration: Anticipates patients remaining on Casatafan for 5–10+ years due to durability, potentially becoming a backbone therapy similar to bevacizumab in colorectal cancer.

Business-Segment Outlook:

• First Line (Peak 20): Focus on the Ip/Nevo backbone to address the 20% primary progression rate; early data shows 7% primary progression with Casatafan/PD-1 and 50% confirmed ORR (doublet); triplet safety data (Casatafan/Ip/Nevo) meets FDA/EMA requirements to start registrational trials immediately upon enrollment.
• Second Line (Peak 1): Targeting CABO backbone; early data shows Median PFS ~14.5 months and OS signal separation; specifically targets the 60% of patients previously exposed to second-generation TKIs (Lenvatinib/Axitinib) who have the worst prognosis.
• Late Line: Monotherapy data shows Median OS of 3 years; aims to combine with Tivozanib to take over monotherapy share and improve PFS/OS over Tivozanib alone.
• Pipeline: Sustainable pipeline of early-stage immunology programs; potential for future bispecific combinations (BMS, Pfizer, Summit) in the first line.

Market and Competitive Outlook:

• Competitive Landscape: Belzutifan (Lumretifan) defined by transient biomarker effect (wanes by 13 weeks) and inability to overcome TKI-induced HIF-2-alpha upregulation; Casatafan aims to be the "best-in-class" HIF-2-alpha inhibitor with durable, deep suppression.
• Pricing/Adoption Strategy: Positioning as a TKI-sparing regimen in the first line to improve quality of life and avoid TKI-related toxicity; leveraging Cabozantinib's strong physician preference in the second line to facilitate rapid adoption of the combination.
• Market Shift: Anticipates changing the paradigm from "TKI-sparing" to "HIF-2-alpha inhibitor as backbone," potentially replacing current monotherapy or combination standards across all lines of therapy.

Macro / Industry Outlook:

• Regulatory: FDA/EMA safety data sets for the first-line triplet are complete and ready for submission to initiate Phase 3 trials at year-end.
• Scientific Trend: Industry recognition of HIF-2-alpha as a critical driver; management notes zero evidence of meaningful resistance development to HIF-2-alpha inhibition, supporting long-term sequencing.
• Biomarkers: Strong correlation established between HIF-2-alpha inhibition depth (measured by EPO and PI-1 suppression) and clinical efficacy (ORR, PFS, OS), suggesting a predictable clinical response across patient populations.

Strategic Initiatives:

• Trials Commencing: Peak 20 (First Line) enrollment to begin end-of-year; Peak 30 (Late Line) development to launch Phase 3.
• Collaborations: Partnerships with BMS, Pfizer, and Summit to test VEGF/VEGF bispecifics combined with Casatafan in the first line; expecting financial terms to be "very financially attractive" to Arcus.
• Dosing Strategy: Utilizing 120mg dose; management notes that even at 50mg (if dose-reduced for anemia), the molecule maintains potent HIF-2-alpha inhibition exceeding Belzutifan's 120mg.
• Safety Mitigation: Proactive management of anemia/hypoxia (targeted side effects) to maintain high dose intensity; expectation of high patient retention despite these on-target effects.

Risks and Headwinds to Outlook:

• Patient Population Variability: Potential for slower OS readouts in the first line due to need for longer follow-up compared to PFS.
• Safety Management: Anemia and hypoxia are expected in all patients; while manageable, high-grade events could necessitate dose reductions or temporary holds, potentially impacting dose intensity.
• Competitive Landscape Evolution: Approval of Belzutifan + Lenvatinib in second line could alter standard of care, though management notes low uptake potential due to toxicity concerns compared to Cabozantinib.
• Trial Execution: Peak 1 control arm may perform worse than benchmarks if the patient population is heavily pre-treated with Lenvatinib, though the trial design is conservative and assumes a high-performing control arm.

Management Tone on the Future:

• Confidence Level: Extremely high; described as "laser-focused," "uniquely positioned," and "best-in-class."
• Forward-Looking Sentiment: Management expresses confidence that the curves will "only get better" as data matures; emphasizes that early OS signals in second line will likely translate to front-line benefits.
• Differentiation: Repeated emphasis that Casatafan offers "hormone" (HIF-2) without the "TKI baggage," positioning it as a transformative therapy capable of changing the standard of care across all lines.
• Hedges: No specific guidance on timelines for commercial launch beyond trial readout expectations; notes that efficacy is consistent across favorable/intermediate/poor risk groups.

Miscellaneous:

• Biomarker Correlation: Data indicates that ~15-20% of patients may have low baseline HIF-2-alpha activity and derive less benefit, but ~80% of the population shows deep biomarker suppression correlating with superior PFS/OS.
• Sequencing: Belief that Casatafan can be sequenced with other agents indefinitely due to lack of resistance and non-overlapping toxicity with IO/TKIs.
• Trial Design: Peak 1 uses all-comers excluding prior HIF-2 exposure in the control arm; Peak 20 is an all-comer Phase 3 study.